Roivant Sciences Ltd. reports developments across a Vant-based biopharmaceutical portfolio, including clinical and regulatory updates from Priovant Therapeutics and other subsidiaries. Recurring coverage centers on brepocitinib, a JAK1/TYK2 inhibitor being developed for autoimmune and inflammatory diseases such as dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris.
Company updates also cover FcRn-targeting antibodies IMVT-1402 and batoclimab, mosliciguat for pulmonary hypertension associated with interstitial lung disease, financial results, share repurchases and technology-related matters involving Genevant’s lipid nanoparticle delivery platform. Roivant news commonly links pipeline progress with subsidiary-level development plans and corporate capital actions.
Priovant, a Roivant (ROIV) company, announced publication of Phase 2 brepocitinib results in cutaneous sarcoidosis in JAMA Dermatology. The randomized, placebo-controlled study enrolled 31 adults for 16 weeks. The primary endpoint, change in a skin disease activity score, improved by 22.3 points with 45 mg daily and 22.2 points with 15 mg, versus 0.7 points with placebo; both comparisons had P<0.0001.
At Week 16, 69% receiving 45 mg achieved clear or almost clear skin with at least a two-category improvement, versus 0% on placebo. Improvements appeared by Week 4 and increased through Week 16. Skin-related quality of life also improved, and no serious adverse events occurred during treatment. Priovant is evaluating 45 mg daily in the ongoing Phase 3 BEACON+ study and expects topline data in calendar year 2028.
Immunovant (IMVT) reported that IMVT-1402 600 mg met the primary endpoint in its difficult-to-treat rheumatoid arthritis trial and released quarterly results. At Week 28, ACR20 response, a measure of joint-symptom improvement, was 92.5% versus 75.6% with placebo (p=0.0139). This randomized withdrawal period included responders to an open-label lead-in. The 300 mg dose did not differ from placebo; secondary disease-activity endpoints numerically favored 600 mg.
Immunovant plans FDA discussions later in 2026 and expects further Sjögren’s development beyond the ongoing Phase 2 trial is unlikely. It expects Graves’ disease and myasthenia gravis data in 2027, and chronic inflammatory demyelinating polyneuropathy data in 2028. Quarterly net loss narrowed to $97.2 million from $126.5 million a year earlier. Cash was $722.3 million; the company expects runway to a potential Graves’ disease launch under its current operating plan.
Roivant (Nasdaq: ROIV) reported second-quarter results with $31.0 million in LISRAYA net product revenue during its first five launch weeks. For the quarter ended September 30, 2026, net loss attributable to Roivant widened to $191.6 million from $113.5 million a year earlier. Cash, cash equivalents and marketable securities totaled $4.2 billion; the company expects this to support operations into profitability.
IMVT-1402 600 mg met its rheumatoid arthritis trial’s primary endpoint in the randomized withdrawal period, but the 300 mg dose did not differ from placebo. Brepocitinib met the primary and all key secondary endpoints in both Phase 3 non-infectious uveitis trials; Priovant plans a supplemental approval application in the first half of 2027. Mosliciguat met Phase 2 endpoints, and its Phase 3 study has started. Immunovant expects further Sjögren’s disease development beyond the ongoing Phase 2 trial is unlikely.
Roivant Social Ventures, whose launch Roivant Sciences (ROIV) supported, announced a six-figure legacy donation to No Patient Left Behind.
The charity is closing out its own institutional work after six years of programs focused on access to medicines and healthcare. Its support for No Patient Left Behind aims to advance drug affordability and access while preserving incentives for medical innovation.
Roivant (ROIV) and Priovant reported that brepocitinib met the primary and all key secondary endpoints in two Phase 3 non-infectious uveitis trials.
Once-daily 45 mg brepocitinib extended median time to treatment failure beyond 48 weeks, versus approximately 12 weeks with placebo in both CLARITY studies (p<0.0001). Pooled results showed steroid-free disease inactivity at Week 48 in 62% of brepocitinib patients versus 20% with placebo. Among eyes with swelling in the central retina at baseline, resolution occurred in 42% versus 4.8%. Both pooled comparisons had p<0.0001. Retinal vascular leakage and patient-reported visual functioning also improved.
No new safety signals emerged; 3% of participants discontinued treatment because of an adverse event. Priovant intends to submit a supplemental New Drug Application for this indication in the first half of 2027.
Immunovant (Nasdaq: IMVT) will report its second fiscal quarter financial results before the market opens on November 9, 2026.
The quarter ended September 30, 2026. Majority stockholder Roivant Sciences (Nasdaq: ROIV) will host a conference call and webcast at 8:00 a.m. ET that day, including an Immunovant business update. An archived webcast will be available on Immunovant’s website afterward.
Roivant (Nasdaq: ROIV) will report second-quarter financial results and provide a business update on November 9, 2026.
The quarter ended September 30, 2026. The live conference call and webcast will begin at 8:00 a.m. ET, with an archived webcast available afterward. Roivant will also host an investor day on December 9, 2026, with in-person and webcast attendance.
Immunovant (IMVT) reported topline results from Period 1 of its proof-of-concept trial of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE), where the study did not achieve statistical significance on the primary endpoint of CLASI-A percent change from baseline at Week 12.
Numerical trends favored IMVT-1402 over placebo on multiple endpoints, and patients with deeper IgG reductions were more likely to show improved clinical responses, but these results did not meet the company’s internal bar to continue IMVT-1402 development in CLE. IMVT-1402 showed a favorable safety and tolerability profile consistent with prior studies, and the company stated that all other clinical development timelines for IMVT-1402 in autoimmune diseases such as Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjogren’s disease remain on track.
Roivant (ROIV)/b) reported topline results from Period 1 of Immunovant’s proof-of-concept trial of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE).The study did not achieve statistical significance on its primary endpoint of percent change from baseline in CLASI-A score at Week 12, and Immunovant plans to stop development of IMVT-1402 in CLE. Numerical trends favored IMVT-1402 over placebo across multiple endpoints, with deeper IgG reductions associated with better clinical responses. IMVT-1402 showed a favorable safety and tolerability profile consistent with prior studies, and all other IMVT-1402 clinical development timelines in autoimmune indications remain on track.
Roivant (ROIV) reported positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and has initiated the Phase 3 PHrontier study.
PHocus met its primary endpoint with a placebo-adjusted pulmonary vascular resistance reduction of -56.3% at Week 16 (p<0.0001). Key secondary endpoints were also met, including a placebo-adjusted +35.2-meter gain in six-minute walk distance (6MWD, p=0.0027) and a -357.7 pg/mL (placebo-adjusted, -53.2%) reduction in NT-proBNP (p=0.0002). Pre-specified exploratory Week 24 analyses showed further placebo-adjusted improvements, with 6MWD rising to +52.7 meters and NT-proBNP falling by -487.1 pg/mL (-75.9%; both nominal p<0.0001).
Mosliciguat was observed to be well tolerated, with adverse events consistent with PH-ILD and a lower cough incidence than placebo (12.1% vs. 18.2%). The ongoing PHrontier trial in PH-ILD has begun enrollment, and results are being presented at the 2026 European Respiratory Society Congress.